Compared to the control group, women with early invasive breast cancer had a significantly higher serum IL-17A concentration both before surgery (P<0.001) and during adjuvant therapy after surgery (P=0.001), as shown in Table 2, Figures 2, 3. The gene discussed is IL17A; the disease is invasive breast carcinoma.